Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1602 of 5804
-
New drug shows promise for controlling rare swelling disorder
Disease control CompletedThe purpose of this study was to evaluate the safety and efficacy of extended dosing of donidalorsen administered subcutaneously (SC), with alternative dosing and/or dose frequency with donidalorsen in participants with hereditary angioedema (HAE).
Phase: PHASE2 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New combo therapy shows promise for older brain cancer patients
Disease control CompletedThe primary objective of Stage 1 is to evaluate the safety of nivolumab consolidation after completion of HD-MTX containing induction chemotherapy in older subjects with PCNSL in terms of a tolerated dose (based on dose-limiting toxicities) for the expansion phase of the study (S…
Phase: PHASE1 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New study tracks Elocta's Long-Term joint protection in hemophilia
Disease control OngoingThis is a 48-month observational, prospective, multicentre study. The overall aim of the study is to evaluate the long-term effectiveness of Elocta treatment on joint health in patients treated prophylactically with Elocta in a real-world setting.
Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Could a thyroid hormone boost oxygen in severe lung failure?
Symptom relief OngoingIt is hypothesized that instillation of Liothyronine Sodium (T3) into the airspace will be safe, well tolerated, and will increase alveolar fluid clearance and decrease inflammation in patients with ARDS, reflected in improved oxygenation index (OI) and oxygenation saturation ind…
Phase: PHASE2 • Sponsor: University of Minnesota • Aim: Symptom relief
Last updated Jun 27, 2026 12:04 UTC
-
Scientists probe immune system to unlock COVID-19 mysteries
Knowledge-focused Recruiting nowThe COntAGIouS trial (COvid-19 Advanced Genetic and Immunologic Sampling; an in-depth characterization of the dynamic host immune response to coronavirus SARS-CoV-2) proposes a transdisciplinary approach to identify host factors resulting in hyper-susceptibility to SARS-CoV-2 inf…
Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
New hope for seniors with breast cancer: drug combo trial targets tough cases
Disease control Recruiting nowThis phase IIa trial studies the side effects of abemaciclib monotherapy in treating patients age 70 years and older with hormone receptor positive, HER2 negative breast cancer that has spread to other places in the body.
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Early liver shunt may reduce need for repeated fluid drains in ascites patients
Disease control CompletedFor this study, the investigators will be collecting data based on patients' random selection to two different approved standard of care treatments for ascites: Subjects will get randomized into either Group A: Large Volume Paracentesis (LVP) with albumin infusion, or Group B: an…
Phase: NA • Sponsor: University of California, Los Angeles • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Could a simple gas help ventilated COVID-19 patients breathe easier?
Disease control CompletedSevere acute respiratory syndrome (SARS-CoV2) due to novel Coronavirus (2019-nCoV) related infection (COVID-19) is characterized by severe ventilation perfusion mismatch leading to refractory hypoxemia. To date, there is no specific treatment available for 2019-nCoV. Nitric oxide…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Can plasma from recovered patients tame severe COVID-19?
Disease control CompletedThis pilot, prospective study will assess the safety and efficacy of COVID-19 convalescent plasma versus standard care as treatment for severe and/or critical COVID-19 (as defined in the inclusion criteria) in adults 18 years of age and older. A total of 350 eligible subjects wil…
Phase: PHASE1 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug shows promise in helping immune system fight advanced cancers
Disease control CompletedThis is a Phase 1b/2 protocol to evaluate pharmacokinetics, safety, efficacy, and pharmacodynamics of PF-06801591, a programmed death-1(PD-1) antagonist monoclonal antibody (mAb) in participants with advanced malignancies. This study consists of 2 parts: Phase 1b part (dose esc…
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy targets cancer's DNA repair weakness
Disease control OngoingThis phase I/II trial studies the side effects and best dose of avelumab with M6620 in treating patients with deoxyribonucleic acid (DNA) damage repair (DDR) deficient solid tumors that have spread to other places in the body (metastatic) or cannot be removed by surgery (unresect…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug combo aims to halt lung cancer growth
Disease control OngoingThis phase Ib trial studies the side effects and best dose of telaglenastat hydrochloride when given together with osimertinib in treating patients with stage IV non-small cell lung cancer and a mutation in the EGFR gene. Telaglenastat hydrochloride and osimertinib may stop the g…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Eye infection breakthrough: new trial tests antivirals to save sight
Disease control TerminatedCytomegalovirus (CMV) is generally a latent and asymptomatic infection in healthy, immunocompetent individuals. In immunocompromised patients CMV is well known to cause a retinitis that can lead to blindness. In immunocompetent patients, however, CMV can cause recurrent inflammat…
Phase: PHASE2, PHASE3 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Maintenance chemo shows promise in slowing mesothelioma
Disease control CompletedWhat is this study about? This study looks at whether continuing chemotherapy with a drug called gemcitabine after initial treatment can help patients with diffuse pleural mesothelioma keep their cancer under control for a longer time. Diffuse pleural mesothelioma is a rare and…
Phase: PHASE2 • Sponsor: National Cancer Institute, Egypt • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New drug combo aims to prevent dangerous transplant complication
Disease control Recruiting nowThis phase I/II trial studies the side effects and best dose of bendamustine when given with or without cyclophosphamide in preventing graft versus host disease (GVHD) in patients undergoing stem cell transplant. Drugs used in chemotherapy, such as bendamustine and cyclophosphami…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug combo shows promise for rare sarcoma
Disease control CompletedSoft tissue sarcoma (STS) is a relatively rare type of malignant tumor with an incidence of 1-2/100000. For unresectable or widely disseminated advanced STS, a combined clinical trial is the best way to obtain evidence-based medical evidence. Anlotinib, a multi-target receptor t…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Inhaled drug aims to save transplanted lungs from silent threat
Disease control TerminatedThe objective of the trial is to assess the long-term safety and efficacy of L-CsA plus Standard of Care (SoC) in the treatment of BOS in single (SLT) and double lung transplant (DLT) recipients.
Phase: PHASE3 • Sponsor: Zambon SpA • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New combo shows promise for stomach cancer patients with hidden HER2 signal
Disease control CompletedA phase II clinical study of trastuzumab in combination with capecitabine and cisplatin (XP) in patients with tissue HER2-negative but serum HER2-positive advanced gastric cancer
Phase: PHASE2 • Sponsor: Asan Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Can a higher dose of ustekinumab rescue Crohn's patients who lost response?
Disease control CompletedThe aim of the study is to investigate the effect of re-induction with ustekinumab ≈6mg/kg IV followed by two different maintenance dosing regimens 90 mg subcutaneous every 8 weeks (Q8W) vs 90 mg subcutaneous every 4 weeks(Q4W) on clinical, biological and pharmacological outcomes…
Phase: PHASE3 • Sponsor: Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Sound waves vs. bone pain: can ultrasound replace radiation?
Symptom relief OngoingThe FURTHER study aims to evaluate the effectiveness and cost-effectiveness of MR-HIFU (alone or in combination with EBRT) compared to EBRT alone, the standard-of-care, as a palliative treatment option to relieve CIBP. The FURTHER study consists of a multicenter, three-armed rand…
Phase: NA • Sponsor: UMC Utrecht • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC